Circadian rhythm disruption by PARP inhibitors correlates with treatment toxicity in patients with ovarian cancer and is a predictor of side effects
This study was funded by the Dr. Rolf Schwiete Stiftung and the MSH Medical School Hamburg, Germany. The MAMOC trial (ClinicalTrials.gov: NCT04227522) was funded by Clovis Oncology, United States.
Authors
- Jalid Sehouli (ORCID: https://orcid.org/0000-0002-5963-6623)
- Nina Nelson (ORCID: https://orcid.org/0000-0002-7551-030X)
- Michael Eichbaum (ORCID: https://orcid.org/0000-0001-5963-3361)
- Mustafa Deryal (ORCID: https://orcid.org/0009-0001-4634-2378)
- Karmen Stankov (ORCID: https://orcid.org/0000-0002-3888-3473)
- Jens Gerber
- Ralf Witteler
- Angela Relógio (ORCID: https://orcid.org/0000-0002-9165-2439)
- Josefin Garmshausen (ORCID: https://orcid.org/0000-0003-1605-1112)
- Ouda Aboumanify (ORCID: https://orcid.org/0000-0003-3191-5441)
- Tomáš Kupec (ORCID: https://orcid.org/0000-0003-0629-8576)
- Gunther Rogmans
- Deeksha Malhan (ORCID: https://orcid.org/0000-0002-5634-3833)
- Bastian Czogalla (ORCID: https://orcid.org/0000-0001-6589-4736)
- Janina Hesse (ORCID: https://orcid.org/0000-0003-0283-3471)
- Martin C. Koch (ORCID: https://orcid.org/0000-0002-9148-2652)
- Jessica Nguyen (ORCID: https://orcid.org/0000-0003-4497-8134)
- Elena Ioana Braicu
- Oliver Tomé
Institutions
- Universität Hamburg (DE)
- Johannes Gutenberg University Mainz (DE)
- Helios Dr. Horst Schmidt Kliniken Wiesbaden (DE)
- Humboldt-Universität zu Berlin (DE)
- MSH Medical School Hamburg – University of Applied Sciences and Medical University (DE)
- Klinik für Frauenheilkunde (DE)
- Städtisches Klinikum Dessau (DE)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- Ansbach University of Applied Sciences (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- St. Vincentius-Kliniken (DE)
- STATinMED (United States) (US)
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
- Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie (DE)
- Klinikum Saarbrücken (DE)
- Charité - Universitätsmedizin Berlin (DE)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- EBioMedicine
- Published
- 2025-05-16
- DOI
- https://doi.org/10.1016/j.ebiom.2025.105764
- Citations
- 3
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 3.14
Funders
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Hexal AG
- Novocure
- Clovis Oncology
- Eisai
- Vifor Pharma
- Boehringer Ingelheim Stiftung
- PharmaMar
- Berlin Institute of Health
- Novartis Pharma